[ad_1]
Sahin, U., Karikó, K. & Türeci, Ö. mRNA-based therapeutics—developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759–780 (2014).
Weng, Y. et al. The challenge and prospect of mRNA therapeutics landscape. Biotechnol. Adv. 40, 107534 (2020).
Rohner, E., Yang, R., Foo, K. S., Goedel, A. & Chien, K. R. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40, 1586–1600 (2022).
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
Walsh, E. E. et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N. Engl. J. Med. 383, 2439–2450 (2020)
Collén, A. et al. VEGFA mRNA for regenerative treatment of heart failure. Nat. Rev. Drug Discov. 21, 79–80 (2022).
Mullard, A. mRNA-based drug approaches phase I milestone. Nat. Rev. Drug Discov. 15, 595 (2016).
A study of VERVE-101 in patients with familial hypercholesterolemia and cardiovascular disease. Clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT05398029?term=verve101&draw=2&rank=1 (2023).
Rybakova, Y. et al. mRNA delivery for therapeutic anti-HER2 antibody expression in vivo. Mol. Ther. 27, 1415–1423 (2019).
Gillmore, J. D. et al. CRISPR–Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493–502 (2021).
Ramaswamy, S. et al. Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc. Natl Acad. Sci. USA 114, E1941–E1950 (2017).
Jiang, L. et al. Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia. Nat. Commun. 11, 5339 (2020).
Karikó, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833–1840 (2008).
Karikó, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165–175 (2005).
Kormann, M. S. D. et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat. Biotechnol. 29, 154–157 (2011).
Leppek, K. et al. Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. Nat. Commun. 13, 1536 (2022).
Asrani, K. H. et al. Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA. RNA Biol. 15, 756–762 (2018).
Wesselhoeft, R. A., Kowalski, P. S. & Anderson, D. G. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat. Commun. 9, 2629 (2018).
Chen, R. et al. Engineering circular RNA for enhanced protein production. Nat. Biotechnol. https://doi.org/10.1038/s41587-022-01393-0 (2022).
Schlake, T., Thess, A., Thran, M. & Jordan, I. mRNA as novel technology for passive immunotherapy. Cell. Mol. Life Sci. 76, 301–328 (2019).
Thess, A. et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol. Ther. 23, 1456–1464 (2015).
Koch, A., Aguilera, L., Morisaki, T., Munsky, B. & Stasevich, T. J. Quantifying the dynamics of IRES and cap translation with single-molecule resolution in live cells. Nat. Struct. Mol. Biol. 27, 1095–1104 (2020).
Bloom, K., van den Berg, F. & Arbuthnot, P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 28, 117–129 (2021).
Sonenberg, N. & Hinnebusch, A. G. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136, 731–745 (2009).
Kahvejian, A., Roy, G. & Sonenberg, N. The mRNA closed-loop model: the function of PABP and PABP-interacting proteins in mRNA translation. Cold Spring Harb. Symp. Quant. Biol. 66, 293–300 (2001).
Hinnebusch, A. G. The scanning mechanism of eukaryotic translation initiation. Annu. Rev. Biochem. 83, 779–812 (2014).
Eisen, T. J. et al. The dynamics of cytoplasmic mRNA metabolism. Mol. Cell 77, 786–799.e10 (2020).
Wang, Z., Day, N., Trifillis, P. & Kiledjian, M. An mRNA stability complex functions with poly(A)-binding protein to stabilize mRNA in vitro. Mol. Cell. Biol. 19, 4552–4560 (1999).
Mangus, D. A., Evans, M. C. & Jacobson, A. Poly(A)-binding proteins: multifunctional scaffolds for the post-transcriptional control of gene expression. Genome Biol. 4, 223 (2003).
Bernstein, P., Peltz, S. W. & Ross, J. The poly(A)-poly(A)-binding protein complex is a major determinant of mRNA stability in vitro. Mol. Cell. Biol. 9, 659–670 (1989).
Aditham, A. et al. Chemically modified mocRNAs for highly efficient protein expression in mammalian cells. ACS Chem. Biol. 17, 3352–3366 (2022).
Sawazaki, R. et al. Characterization of the multimeric structure of poly(A)-binding protein on a poly(A) tail. Sci. Rep. 8, 1455 (2018).
Kühn, U. & Pieler, T. Xenopus poly(A) binding protein: functional domains in RNA binding and protein-protein interaction. J. Mol. Biol. 256, 20–30 (1996).
Coombes, C. E. & Boeke, J. D. An evaluation of detection methods for large lariat RNAs. RNA 11, 323–331 (2005).
Katolik, A. et al. Regiospecific solid-phase synthesis of branched oligoribonucleotides that mimic intronic lariat RNA intermediates. J. Org. Chem. 79, 963–975 (2014).
Escorihuela, J. et al. Direct covalent attachment of DNA microarrays by rapid thiol-ene “click” chemistry. Bioconjug. Chem. 25, 618–627 (2014).
Greenberg, M. M. Attachment of reporter and conjugate groups to the 3′ termini of oligonucleotides. Curr. Protoc. Nucleic Acid Chem. https://doi.org/10.1002/0471142700.nc0405s02 (2001).
El-Sagheer, A. H. & Brown, T. Single tube gene synthesis by phosphoramidate chemical ligation. Chem. Commun. 53, 10700–10702 (2017).
Kalinowski, M. et al. Phosphoramidate ligation of oligonucleotides in nanoscale structures. ChemBioChem 17, 1150–1155 (2016).
Ehret, F., Zhou, C. Y., Alexander, S. C., Zhang, D. & Devaraj, N. K. Site-specific covalent conjugation of modified mRNA by tRNA guanine transglycosylase. Mol. Pharm. 15, 737–742 (2018).
Zhang, D. et al. Site-specific and enzymatic cross-linking of sgRNA enables wavelength-selectable photoactivated control of CRISPR gene editing. J. Am. Chem. Soc. 144, 4487–4495 (2022).
Fantoni, N. Z., El-Sagheer, A. H. & Brown, T. A hitchhiker’s guide to click-chemistry with nucleic acids. Chem. Rev. 121, 7122–7154 (2021).
Warminski, M., Kowalska, J. & Jemielity, J. Solid-phase synthesis of RNA 5′-azides and their application for labeling, ligation, and cyclization via click chemistry. Curr. Protoc. Nucleic Acid Chem. 82, e112 (2020).
Kühn, U. & Wahle, E. Structure and function of poly(A) binding proteins. Biochim. Biophys. Acta 1678, 67–84 (2004).
Deo, R. C., Bonanno, J. B., Sonenberg, N. & Burley, S. K. Recognition of polyadenylate RNA by the poly(A)-binding protein. Cell 98, 835–845 (1999).
Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283–289 (2021).
Gilleron, J. et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31, 638–646 (2013).
Wang, X. et al. Three-dimensional intact-tissue sequencing of single-cell transcriptional states. Science 361, eaat5691 (2018).
Zeng, H. et al. Integrative in situ mapping of single-cell transcriptional states and tissue histopathology in a mouse model of Alzheimer’s disease. Nat. Neurosci. 26, 430–446 (2023).
Zeng, H. et al. Spatially resolved single-cell translatomics at molecular resolution. Science 380, eadd3067 (2023).
Xiang, K. & Bartel, D. P. The molecular basis of coupling between poly(A)-tail length and translational efficiency. eLife 10, e66493 (2021).
Li, X. et al. Generation of destabilized green fluorescent protein as a transcription reporter. J. Biol. Chem. 273, 34970–34975 (1998).
Nicholson-Shaw, A. L., Kofman, E. R., Yeo, G. W. & Pasquinelli, A. E. Nuclear and cytoplasmic poly(A) binding proteins (PABPs) favor distinct transcripts and isoforms. Nucleic Acids Res. 50, 4685–4702 (2022).
Perzanowska, O., Smietanski, M., Jemielity, J. & Kowalska, J. Chemically modified poly(A) analogs targeting PABP: structure activity relationship and translation inhibitory properties. Chemistry 28, e202201115 (2022).
Görlach, M., Burd, C. G. & Dreyfuss, G. The mRNA poly(A)-binding protein: localization, abundance, and RNA-binding specificity. Exp. Cell. Res. 211, 400–407 (1994).
Schäfer, I. B. et al. Molecular basis for poly(A) RNP architecture and recognition by the Pan2–Pan3 deadenylase. Cell 177, 1619–1631.e21 (2019).
Webster, M. W. et al. mRNA deadenylation is coupled to translation rates by the differential activities of Ccr4–Not nucleases. Mol. Cell 70, 1089–1100.e8 (2018).
Dehlin, E., Wormington, M., Körner, C. G. & Wahle, E. Cap-dependent deadenylation of mRNA. EMBO J. 19, 1079–1086 (2000).
Ruud, K. A., Kuhlow, C., Goss, D. J. & Browning, K. S. Identification and characterization of a novel cap-binding protein from Arabidopsis thaliana. J. Biol. Chem. 273, 10325–10330 (1998).
Shestakova, E. D., Smirnova, V. V., Shatsky, I. N. & Terenin, I. M. Specific mechanisms of translation initiation in higher eukaryotes: the eIF4G2 story. RNA 29, 282–299 (2023).
Ho, J. J. D. et al. Systemic reprogramming of translation efficiencies on oxygen stimulus. Cell Rep. 14, 1293–1300 (2016).
Moerke, N. J. et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128, 257–267 (2007).
Jang, D.-I. et al. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int. J. Mol. Sci. 22, 2719 (2021).
Giannini, E. G., Testa, R. & Savarino, V. Liver enzyme alteration: a guide for clinicians. CMAJ 172, 367–379 (2005).
Kumar, A., Zhang, J. & Yu, F.-S. X. Toll-like receptor 3 agonist poly(I:C)-induced antiviral response in human corneal epithelial cells. Immunology 117, 11–21 (2006).
Okahira, S. et al. Interferon-beta induction through Toll-like receptor 3 depends on double-stranded RNA structure. DNA Cell Biol. 24, 614–623 (2005).
Rothgangl, T. et al. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nat. Biotechnol. 39, 949–957 (2021).
Robson, A. Three different therapies to target PCSK9. Nat. Rev. Cardiol. 18, 541 (2021).
Nelson, C. E. et al. Long-term evaluation of AAV–CRISPR genome editing for Duchenne muscular dystrophy. Nat. Med. 25, 427–432 (2019).
Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429–434 (2021).
Qiu, M. et al. Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3. Proc. Natl Acad. Sci. USA 118, e2020401118 (2021).
Zhou, J. et al. Dual sgRNAs facilitate CRISPR/Cas9-mediated mouse genome targeting. FEBS J. 281, 1717–1725 (2014).
Park, J. et al. Short poly(A) tails are protected from deadenylation by the LARP1–PABP complex. Nat. Struct. Mol. Biol. https://doi.org/10.1038/s41594-023-00930-y (2023).
Arevalo, C. P. et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science 378, 899–904 (2022).
Foy, S. P. et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature 615, 687–69 (2023).
Dong, Y. et al. DNA functional materials assembled from branched DNA: design, synthesis, and applications. Chem. Rev. 120, 9420–9481 (2020).
Horn, T., Chang, C. A. & Urdea, M. S. Chemical synthesis and characterization of branched oligodeoxyribonucleotides (bDNA) for use as signal amplifiers in nucleic acid quantification assays. Nucleic Acids Res. 25, 4842–4849 (1997).
Chen, H. et al. Branched, chemically modified poly(A) tails enhance the translation capacity of mRNA. Sequence Read Archive https://www.ncbi.nlm.nih.gov/sra/PRJNA1072971 (2024).
Anzalone, A. V. et al. Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing. Nat. Biotechnol. 40, 731–740 (2022).
Maqvi News #Maqvi #Maqvinews #Maqvi_news #Maqvi#News #info@maqvi.com
[ad_2]
Source link
